Advanced care planning during the COVID-19 pandemic: ceiling of care decisions and their implications for observational data.


Journal

BMC palliative care
ISSN: 1472-684X
Titre abrégé: BMC Palliat Care
Pays: England
ID NLM: 101088685

Informations de publication

Date de publication:
11 Jan 2021
Historique:
received: 20 08 2020
accepted: 03 01 2021
entrez: 12 1 2021
pubmed: 13 1 2021
medline: 22 1 2021
Statut: epublish

Résumé

Observational studies investigating risk factors in coronavirus disease 2019 (COVID-19) have not considered the confounding effects of advanced care planning, such that a valid picture of risk for elderly, frail and multi-morbid patients is unknown. We aimed to report ceiling of care and cardiopulmonary resuscitation (CPR) decisions and their association with demographic and clinical characteristics as well as outcomes during the COVID-19 pandemic. Retrospective, observational study conducted between 5th March and 7th May 2020 of all hospitalised patients with COVID-19. Ceiling of care and CPR decisions were documented using the Recommended Summary Plan for Emergency Care and Treatment (ReSPECT) process. Unadjusted and multivariable regression analyses were used to determine factors associated with ceiling of care decisions and death during hospitalisation. A total of 485 patients were included, of whom 409 (84·3%) had a documented ceiling of care; level one for 208 (50·9%), level two for 75 (18·3%) and level three for 126 (30·8%). CPR decisions were documented for 451 (93·0%) of whom 336 (74·5%) were 'not for resuscitation'. Advanced age, frailty, White-European ethnicity, a diagnosis of any co-morbidity and receipt of cardiovascular medications were associated with ceiling of care decisions. In a multivariable model only advanced age (odds 0·89, 0·86-0·93 p < 0·001), frailty (odds 0·48, 0·38-0·60, p < 0·001) and the cumulative number of co-morbidities (odds 0·72, 0·52-1·0, p = 0·048) were independently associated. Death during hospitalisation was independently associated with age, frailty and requirement for level two or three care. Ceiling of care decisions were made for the majority of patients during the COVID-19 pandemic, broadly in line with known predictors of poor outcomes in COVID-19, but with a focus on co-morbidities suggesting ICU admission might not be a reliable end-point for observational studies where advanced care planning is routine.

Sections du résumé

BACKGROUND BACKGROUND
Observational studies investigating risk factors in coronavirus disease 2019 (COVID-19) have not considered the confounding effects of advanced care planning, such that a valid picture of risk for elderly, frail and multi-morbid patients is unknown. We aimed to report ceiling of care and cardiopulmonary resuscitation (CPR) decisions and their association with demographic and clinical characteristics as well as outcomes during the COVID-19 pandemic.
METHODS METHODS
Retrospective, observational study conducted between 5th March and 7th May 2020 of all hospitalised patients with COVID-19. Ceiling of care and CPR decisions were documented using the Recommended Summary Plan for Emergency Care and Treatment (ReSPECT) process. Unadjusted and multivariable regression analyses were used to determine factors associated with ceiling of care decisions and death during hospitalisation.
RESULTS RESULTS
A total of 485 patients were included, of whom 409 (84·3%) had a documented ceiling of care; level one for 208 (50·9%), level two for 75 (18·3%) and level three for 126 (30·8%). CPR decisions were documented for 451 (93·0%) of whom 336 (74·5%) were 'not for resuscitation'. Advanced age, frailty, White-European ethnicity, a diagnosis of any co-morbidity and receipt of cardiovascular medications were associated with ceiling of care decisions. In a multivariable model only advanced age (odds 0·89, 0·86-0·93 p < 0·001), frailty (odds 0·48, 0·38-0·60, p < 0·001) and the cumulative number of co-morbidities (odds 0·72, 0·52-1·0, p = 0·048) were independently associated. Death during hospitalisation was independently associated with age, frailty and requirement for level two or three care.
CONCLUSION CONCLUSIONS
Ceiling of care decisions were made for the majority of patients during the COVID-19 pandemic, broadly in line with known predictors of poor outcomes in COVID-19, but with a focus on co-morbidities suggesting ICU admission might not be a reliable end-point for observational studies where advanced care planning is routine.

Identifiants

pubmed: 33430850
doi: 10.1186/s12904-021-00711-8
pii: 10.1186/s12904-021-00711-8
pmc: PMC7797882
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

10

Subventions

Organisme : British Heart Foundation
ID : CH/13/1/30086
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/15/9/31092
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/18/44/33792
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/CRTF/20/24071
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/12/80/29821
Pays : United Kingdom

Commentaires et corrections

Type : ErratumIn

Références

Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Intensive Care Med. 2017 Aug;43(8):1105-1122
pubmed: 28676896
J Am Heart Assoc. 2020 Apr 7;9(7):e016509
pubmed: 32233753
Br J Anaesth. 2020 Sep;125(3):253-258
pubmed: 32560912
BMJ. 2017 Feb 28;356:j876
pubmed: 28246080
Lancet. 2020 Apr 4;395(10230):1137-1144
pubmed: 32178768
Lancet. 2020 May 2;395(10234):1421-1422
pubmed: 32330427
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Intensive Care Med. 2012 Oct;38(10):1647-53
pubmed: 22777516
JAMA Intern Med. 2020 Oct 1;180(10):1345-1355
pubmed: 32667669
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
JAMA. 2020 Apr 21;323(15):1499-1500
pubmed: 32159735
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
CMAJ. 2005 Aug 30;173(5):489-95
pubmed: 16129869
JAMA Intern Med. 2020 Nov 1;180(11):1436-1447
pubmed: 32667668
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
N Engl J Med. 2020 Jul 9;383(2):e6
pubmed: 32374958
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
J Infect. 2020 Jun;80(6):639-645
pubmed: 32240670
Resuscitation. 2020 Jun;151:18-23
pubmed: 32283117
JAMA. 2020 May 12;323(18):1771-1772
pubmed: 32219360
Heart. 2020 Oct;106(19):1461-1462
pubmed: 32759292
Geriatrics (Basel). 2020 May 06;5(2):
pubmed: 32384707
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632

Auteurs

Sam Straw (S)

Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.

Melanie McGinlay (M)

Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Michael Drozd (M)

Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.

Thomas A Slater (TA)

Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.

Alice Cowley (A)

Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Stephe Kamalathasan (S)

Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Nicholas Maxwell (N)

School of Medicine, University of Leeds, Leeds, UK.

Rory A Bird (RA)

School of Medicine, University of Leeds, Leeds, UK.

Aaron O Koshy (AO)

Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.

Milos Prica (M)

Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Peysh A Patel (PA)

Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Samuel D Relton (SD)

Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.

John Gierula (J)

Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.

Richard M Cubbon (RM)

Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.

Mark T Kearney (MT)

Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.

Klaus K Witte (KK)

Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK. k.k.witte@leeds.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH